Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency

Journal of Controlled Release

Volumn 110, Issue 3, 2006, Pages 566-573

  Kazzaz, Jina ^a   Singh, Manmohan ^a   Ugozzoli, Mildred ^a   Chesko, James ^a   Soenawan, Elawati ^a   O'Hagan, Derek T ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

HIV; Microparticle; MPL; Neisseria meningitidis; RC529; Vaccine

Indexed keywords

DISEASES; IMMUNOLOGY; PROTEINS; SURFACE ACTIVE AGENTS; VACCINES;

HIV; MICROPARTICLE; MPL; RC529;

LIPIDS;

BACTERIAL ANTIGEN; DICHLOROMETHANE; DOCUSATE SODIUM; GLYCOPROTEIN GP 120; LIPOPOLYSACCHARIDE; PHOSPHORYL LIPID A; POLYGLACTIN; RC 529; RG 503; UNCLASSIFIED DRUG;

ARTICLE; BACTERICIDAL ACTIVITY; CPG ISLAND; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULARY; DRUG POTENCY; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; EVAPORATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN STABILITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHO CELLS; CRICETINAE; CRICETULUS; LACTIC ACID; LIPID A; MICE; MICROBIAL SENSITIVITY TESTS; MICROSPHERES; NEISSERIA MENINGITIDIS; POLYGLYCOLIC ACID; POLYMERS;

EID: 31644446786     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.10.010     Document Type: Article

References (40)

1. R.K. Gupta, B.E. Rost, E. Relyveld, and G.R. Siber Adjuvant properties of aluminum and calcium compounds Pharm. Biotechnol. 6 1995 229 248
2. R.K. Gupta, and G.R. Siber Adjuvants for human vaccines-current status, problems and future prospects Vaccine 13 1995 1263 1276
3. D. O'Hagan, and M. Singh Microparticles as vaccine adjuvants and delivery systems Expert Rev. Vaccines 2 2003 269 283
4. H. Okada, H. Toguchi, Biodegradable microspheres in drug delivery, 12 (1995) 1-99.
5. S.D. Putney, and P.A. Burke Improving protein therapeutics with sustained-release formulations [published erratum appears in Nat Biotechnol 1998 May;16(5):478] Nat. Biotechnol. 16 1998 153 157
6. Y. Tabata, and Y. Ikada Macrophage phagocytosis of biodegradable microspheres composed of l-lactic acid/glycolic acid homo- and copolymers J. Biomed. Mater. Res. 22 1988 837 858
7. K.D. Newman, P. Elamanchili, G.S. Kwon, and J. Samuel Uptake of poly(d,l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo J. Biomed. Mater. Res. 60 2002 480 486
8. K.J. Maloy, A.M. Donachie, D.T. O'Hagan, and A.M. Mowat Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles Immunology 81 1994 661 667
9. 1 cells Vaccine 13 1995 1741 1749
10. J. Kazzaz, J. Neidleman, M. Singh, G. Ott, and D.T. O'Hagan Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1 J. Control. Release 67 2000 347 356
11. G.R. Otten, M. Schaefer, C. Greer, M. Calderon-Cacia, D. Coit, J. Kazzaz, A. Medina-Selby, M. Selby, M. Singh, M. Ugozzoli, J. zur Megede, S. Barnett, D. O'Hagan, J. Donnelly, and J.B. Ulmer Induction of broad and potent anti-HIV immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed PLG microparticles J. Virol. 77 2003 6087 6092
12. M. Singh, J. Kazzaz, J. Chesko, E. Soenawan, M. Ugozzoli, M. Giuliani, M. Pizza, R. Rappuoli, and D.T. O'Hagan Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B J. Pharm. Sci. 93 2004 273 282
13. R. Medzhitov, and C.A. Janeway Jr. An ancient system of host defense Curr. Opin. Immunol. 10 1998 12 15
14. A. Bendelac, and R. Medzhitov Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity J. Exp. Med. 195 2002 F19 F23
15. R. Medzhitov Toll-like receptors and innate immunity Nat. Rev. Immunol. 1 2001 135 145
16. M.D. Cunningham, R.A. Shapiro, C. Seachord, K. Ratcliffe, L. Cassiano, and R.P. Darveau CD14 employs hydrophilic regions to "capture" lipopolysaccharides J. Immunol. 164 2000 3255 3263
17. M. Muzio, D. Bosisio, N. Polentarutti, G. D'Amico, A. Stoppacciaro, R. Mancinelli, C. van't Veer, G. Penton-Rol, L.P. Ruco, P. Allavena, and A. Mantovani Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells J. Immunol. 164 2000 5998 6004
18. E. Lien, T.K. Means, H. Heine, A. Yoshimura, S. Kusumoto, K. Fukase, M.J. Fenton, M. Oikawa, N. Qureshi, B. Monks, R.W. Finberg, R.R. Ingalls, and D.T. Golenbock Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide J. Clin. Invest. 105 2000 497 504
19. R.B. Yang, M.R. Mark, A.L. Gurney, and P.J. Godowski Signaling events induced by lipopolysaccharide-activated toll-like receptor 2 J. Immunol. 163 1999 630
20. C.J. Kirschning, H. Wesche, T. Merrill Ayres, and M. Rothe Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide J. Exp. Med. 188 1998 2091 2097
21. A.G. Johnson Molecular adjuvants and immunomodulators: new approaches to immunization Clin. Microbiol. Rev. 7 1994 277 289
22. J.T. Ulrich, and K.R. Myers Monophosphoryl lipid A as an adjuvant: past experiences and new directions Vaccine Design: The Subunit and Adjuvant Approach 1995 Plenum Press New York 465 524
23. J.R. Baldridge, Y. Yorgensen, J.R. Ward, and J.T. Ulrich Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration Vaccine 18 2000 2416 2425
24. 1 Vaccine 17 1999 2517 2527
25. C.A. Salkowski, G.R. Detore, and S.N. Vogel Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages Infect. Immun. 65 1997 3239 3247
26. M.E. Johnson, J.R. Ward, and J.T. Evans Microsphere formulations of protein antigens and TLR-4 adjuvants elicit the strongest comprehensive immune response-Abstract #30 30th Annual Meeting of the Controlled Release Society 2003
27. Corixa, http://www.corixa.com/default.asp?pid=infect - Accessed February 22, 2005.
28. P.L. Alonso, J. Sacarlal, J.J. Aponte, A. Leach, E. Macete, J. Milman, I. Mandomando, B. Spiessens, C. Guinovart, M. Espasa, Q. Bassat, P. Aide, O. Ofori-Anyinam, M.M. Navia, S. Corachan, M. Ceuppens, M.C. Dubois, M.A. Demoitie, F. Dubovsky, C. Menendez, N. Tornieporth, W.R. Ballou, R. Thompson, and J. Cohen Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial Lancet 364 2004 1411 1420
29. D.M. Harper, E.L. Franco, C. Wheeler, D.G. Ferris, D. Jenkins, A. Schuind, T. Zahaf, B. Innis, P. Naud, N.S. De Carvalho, C.M. Roteli-Martins, J. Teixeira, M.M. Blatter, A.P. Korn, W. Quint, and G. Dubin Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 364 2004 1757 1765
30. Corixa, http://www.corixa.com/default.asp?pid=product_detail and ID=34 - Accessed February 22, 2005.
31. M. Singh, G. Ott, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly, and D.T. O'Hagan Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA Pharm. Res. 18 2001 1476 1479
32. M. Pizza, V. Scarlato, V. Masignani, M.M. Giuliani, B. Arico, M. Comanducci, G.T. Jennings, L. Baldi, E. Bartolini, B. Capecchi, C.L. Galeotti, E. Luzzi, R. Manetti, E. Marchetti, M. Mora, S. Nuti, G. Ratti, L. Santini, S. Savino, M. Scarselli, E. Storni, P. Zuo, M. Broeker, E. Hundt, B. Knapp, E. Blair, T. Mason, H. Tettelin, D.W. Hood, A.C. Jeffries, N.J. Saunders, D.M. Granoff, J.C. Venter, E.R. Moxon, G. Grandi, and R. Rappuoli Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing Science 287 2000 1816 1820
33. I.K. Srivastava, L. Stamatatos, E. Kan, M. Vajdy, Y. Lian, S. Hilt, L. Martin, C. Vita, P. Zhu, K.H. Roux, L. Vojtech, C.M.D, J. Donnelly, J.B. Ulmer, and S.W. Barnett Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate J. Virol. 77 2003 11244 11259
34. H.L. Davis, R. Weeranta, T.J. Waldschmidt, L. Tygrett, J. Schorr, and A.M. Krieg CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen J. Immunol. 160 1998 870 876
35. J.R. Baldridge, and R.T. Crane Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines Methods 19 1999 103 107
36. S.S. Wildes, and A.R. Tunkel Meningococcal vaccines: a progress report BioDrugs 16 2002 321 329
37. J. Chesko, J. Kazzaz, M. Ugozzoli, E. Kan, I. Srivastava, T. O'Hagan, and M. Singh Adsorption of a novel recombinant glycoprotein from HIV (env gp120dv2) to anionic PLG microparticles retains structural integrity, while encapsulation in PLG microparticles does not Pharm. Res. 21 12 2004 Dec 2148 2152
38. D.T. O'Hagan Prospects for the Development of New and Improved Vaccines Through the Use of Microencapsulation Technology, New Generation Vaccines 1997 Marcel Dekker, Inc. New York 215 228
39. R.A. Wall Meningococcal disease: treatment and prevention Ann. Med. 34 2002 624 634
40. C.M. Snapper, and W.E. Paul Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production Science 236 1987 944 947